These pooled resources will be directed to a few high-priority diseases, identified through an evaluation of the marginal benefit of additional R&D. Japan’s focused strategy to champion stem-cell R&D should serve as a model for other countries.
这些集中起来的资源将被用于一些较紧迫的疾病，通过对研发增量的边际收益来评估。日本集中资源推进干细胞研发的战略可以作为其他国家的榜样。